Member Info for stu485

HT,

I’m genuinely surprised at you.

There’s a massively important question unanswered and you’re happy to overlook it !

Each to there own I suppose.

Good luck anyway.

AIMO

JFH, nope 20mins tops and not my entire every breathing moment…like some😉

BHOLD,

Go read my previous PENN paper post, I’m not digging it out for you it’s still on the board.

Within you will read PENN’s explanation of the difficulties , magnitude and shortage of specialist resources to run Car-T trials.

Do a little research and you’ll also find PENN are busy conducting their own Car -T trials .

Now consider the wording within the recent RNS that Hemo’ “hope” PENN will participate.

Put all that together and i conclude, H Car -T AML trials will likely never happen at PENN.

AIMO

Mr I,

A fair question.

Just to correct your interpretation of my previous post on funding.

I have not stated I’m expecting a funding RNS next week.

I do expect a non-dilutive funding RNS through other product options ( not H Car-T), soon.

This being a company objective (non dilutive funding) expressed in June.

Why then would the cause of the PENN issue still be important?

Very simply, if the cause is specific to the proposed H Car-T AML trial proposal and not a generic problem, then even you should realize, that’s very bad news for Hemo’s lead product.

AIMO

JFH,

Yes ,

you and your mates have discussed everything other than the key piece of information within the recent RNS.

It’s called “ distraction” and will now hopefully be obvious to all.

I don’t suppose you’d like to answer the important question I’ve raised?

Why PENN are no longer prepared to conduct the HCar-T trial as Hemo’ had expected?

No of course not !… DISTRACTION

Now you and your mates carry on and quickly overwrite my posts , as usual.

AIMO

Firstly,

Yes there is a delay !

RNS statement;

“Although we had hoped to start the trials sooner”

I believe it also no longer possible to achieve preliminary results of three patients by December as was the prior expectation.

The delay may have intensified the urgency for further funding but an equally concerning question, unanswered within the RNS communication is, what’s the cause of the delay?

Let’s not forget the previous grandstanding of the collaboration with PENN, the premier Car-T research and trial facility.

What’s now changed at PENN resulting in the facility no longer able/willing to conduct the H Car-T AML trial as Hemo’ had previously expected?

I have previously posted a PENN paper explaining the resourcing issue associated with Car-T trials and associated bottlenecks.

This may well be the cause and reason Hemo’ have had to jump to an alternative site for commencement of trials. However , it may not be and there are other scenarios more concerning to investors and their risk/reward assessment.

The fact is, we do not know in any reasonable detail why PENN can not or will not proceed with trials as Hemo’ expected.

The company now only “hopes” PENN will actually participate. Personally I don’t think they ever will, for reasons of limited resources and preferred competing Car-T trials .

The question of why PENN cannot schedule the Hemo’ Car-T AML trials is a very important one!

HT and other genuine large shareholders, should come together and demand an answer to the question:

Q. Can you please advise the specific reasons PENN are unable to schedule the H Car-T trials as expected and are those reasons generic to all Car-T trials OR specific to the circumstances of the proposed HCar-T trial ?

A perfectly reasonable question to ask.

Stay in the dark or find out !

AIMO

Hik’ you couldn’t be more wrong!

The company has announced of a delay and issues with PENN.

“Imminent” has now changed to “soon” and worryingly, the company only “hope” PENN will actually participate!

All understand funds are very stretched, no debate necessary!

Delay only increases the urgency in achieving the company objective of securing non- dilutive financing(June).

Presently my trust in the company actually meeting their non-dilutive financing objective advised, remains.

As time ticks on, it too is being stretched!

Lets see what next week brings.

Ps JFH very active today through his Proxy Mr I.

AIMO

Mr I ,

I wrongly accepted your praise for predicting the recent RNS. I was only part correct!

There was no mention of the new indication (ALL), confirmation by the third party previously mentioned or the FDA, for inclusion in trials.

So, the next RNS, I’d expect imminently, (assuming no clinical holds etc,) will probably be that confirmation, maybe even FDA fast track designation for ALL.

Ps.

No Mr I, ..1+1 🤔

2 indications does not double the MCap !

It will change the maths of trial costs though.

Pps.

Having now exposed JFH’s argument as having no substance in real world examples, goodbye and good luck all.

AIMO

The Rat…Reasoning & Truth.

…so that’s a, NO i can’t substantiate my argument from JFH!

That’s all i need to know.

AIMO

Jfh,

None of your old posts contain a single example as detailed , i’ve already looked!

So are you going to post one to support your argument or not ?…just one?

Surely you would ( if there was one!) just to put me in my place and properly demonstrate your argument.

AIMO

JFh

“The SP being “destroyed” by shorters/traders argument is utter rubbish and only peddled out by those with a dubious motive to do so!”

Orly,

Egotistical posts !?

The most important debate raging right now is;

Will H Car-T phase1 trials and early data for r/r AML , result in a positive SP re-rate and inflow of non-dilutive financing or not. JFH suggests it will and I suggest it won’t.

The difference? I’ve posted real world examples to support my arguments where, even with FDA fast track designation and expansion to second dose Phase1 Car-T r/r AML, the SP dial did not move and non-dilutive funding did not follow.

Arguing for JFH or any others to substantiate their polar opposite argument with any ( just one), real world example to support their Hypothesis, is not egotistical !

JFH has many Car-T r/r AML trial examples to choose from, even those using the same FLt-3 target.

He’s offered … none.

How strange!

AIMO

Orly,

So you agree , it wasn’t shorters !

The SP being “destroyed” by shorters/traders argument is utter rubbish and only peddled out by those with a dubious motive to do so!

AIMO

JFH,

So that’s two straightforward questions asked of you today.

How many did you answer…none !

I doubt it’s just me wondering why .

Good night.

AIMO

JFH,

Yes that’s correct .

A real World example of a Biotech who’s SP and investment fortunes were NOT positively impacted by commencement of Phase 1 clinical trial , first patient dosed , Car-T r/r AML .

BUT

Your argument determines, that can’t possibly be true !

So rather than try and pick holes in my example, all here would no doubt be reassured by a real world example of yours, that demonstrates as you claim, a re-rate in SP and inward investment flow at Phase1 first patient dosed Car-T r/r AML and early data.

Just one will do ????

AIMO

Cons,

No problem!

So the example of Caribou Bio was given as a Car-T potential treatment for r/r AML , FDA fast track designation

at stage two dose escalation within Phase1 clinical trial , to demonstrate;

There was NO tick up in company SP at announcement of first patient dosed & no subsequent outside investment within this particular AML company product to date !

This being the point I’ve made on a number of occasions,

…don’t think all falls into place at phase1 trial !

Evidently it does not in the instance of the above ,real world example.

The question of it not being of comparison to Hemo’ as Allogenic v’s Autologous is ridiculous!

Both Car-T potential treatments for r/r AML.

Yes, Allogenic is different for good reason! It’s an off the shelf solution of which the market should react even more favorably given it’s inherent advantages…the market did not.

I’m surprised HK would want to highlight a point which in fact only strengthens my argument !

So the question answered.

Now mine, can HK or any other detail a real world example of a Biotech’s SP raise and inward investment coming at first patient dose Car-T r/r AML phase1 ?

….again, i wont be holding my breath for a response !

Good evening.

AIMO

JFH,

Well, I suspected you’d struggle to offer a plausible answer but to not even attempt one, …that’s not like you!?

Anyway, have a good evening.

AIMO

Jfh,

Last attempt to tease an answer from you .

*Why’s no one buying in when trials “imminent” ?

I see i hit a nerve making public the FACT other micro Biotechs with MCaps less than that of Hemo’ exist with FDA approved r/r AML trials for potential cures ,in progress.

You’ve all of a sudden introduced lots of caveats to your claim , where previously there were none .

Very telling.

* sufficient to move SP out of your previously stated sideways trading band

AIMO

JFH,

Lot’s of entertaining words but, you didn’t actually answer the question.

*Why’s no one buying in when trials “imminent” ?

Ps. Do you know there are micro biotech’s with MCap’s less than Hemo’ with FDA approved clinical trials in progress for r/r AML ?…FACT.

* sufficient to move SP out of your previously stated sideways trading band.

AIMO

Mr I,

Thank you.

Regarding non-dilutive financing, very soon i hope .

The company made the statement in June , so maybe already overdue.

That’s the best i can offer I’m afraid.

AIMO

JFH,

I think it allowable to ask you a reasonable question.

Don’t you want to put forward an answer ?

AIMO

JFH,

As others have said, it is entertaining you being so enthusiastically WRONG !!

Let’s suspend reality for a moment and consider your avid conviction’s that, at commencement of clinical trials and early data , SP will re-rate and financing flood inwardly.

Why then on announcement of “imminent” trials , no one’s buying and the SP remains in that sideways trading band you mentioned?

Could it be that investors now understand the significant cash requirements for trials and that proving safety does not move the dial in AML until meaningful durability is also demonstrated?

Don’t let that minor detail get in the way of your Hypothesis though and please carry on, it’s fun 😉

AIMO